Synthesis and preliminary PET study of the 5-HT7 receptor antagonist [11C]DR4446

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 45, Issue 10, 2002, Pages 857-866

  Zhang, Ming Rong ^a,b,c   Haradahira, Terushi ^a   Maeda, Jun ^a,b,c   Okauchi, Takashi ^a,b,c   Kida, Takayo ^a,b,c   Obayashi, Shigeru ^a,b   Suzuki, Kazutoshi ^a   Suhara, Tetsuya ^a,b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c 141 0032   (Japan)

Author keywords

5 HT7 receptor; Carbon 11; DR4446; PET

Indexed keywords

BRAIN; CARBON; METABOLITES; SODIUM COMPOUNDS;

5-HT7 RECEPTOR; BRAIN REGIONS; CARBON-11; DR4446; HIGH SELECTIVITY; RADIOCHEMICAL PURITY; RECEPTOR ANTAGONISTS; SPECIFIC ACTIVITY; SPECIFIC BINDING; SYNTHESISED;

POSITRON EMISSION TOMOGRAPHY;

1 METHYL 2A [4 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)BUTYL] 2A,3,4,5 TETRAHYDRO 1H BENZ[CD]INDOL 2 ONE; 1 METHYL 2A [4 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)BUTYL] 2A,3,4,5 TETRAHYDRO 1H BENZ[CD]INDOL 2 ONE C 11; CARBON 11; DR 4446; DRUG METABOLITE; METHYL IODIDE; METHYL IODIDE C 11; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SODIUM DERIVATIVE; SODIUM HYDRIDE; TRACER; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG POTENCY; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MONKEY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRECURSOR; RADIOACTIVITY; THALAMUS;

EID: 0036735067     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlcr.606     Document Type: Article

References (23)

1. Eglen RM, Jasper JR, Chang DJ, Martin GR. Pharmacol Sci 1997; 18: 104-107.
2. Vanhoenacker P, Haegeman G, Leysen JE. Trends Pharmacol Sci 2000; 21: 70-77.
3. Johns BJ, Blackburn TP. Pharmacol Biochem Behav 2002; 71: 555-568.
4. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley DR. J Biol Chem 1993; 268: 18200-18204.
5. Kinsery AM, Wainwright A, Heaven R, Sirnathsinghji DJ, Oliver KR. Brain Res Mol Brain Res 2001; 88: 194-198.
6. Plassat JL, Amlaiky N, Hen R. Mol Pharm 1993; 44: 229-236.
7. Tsou AP, Kosaka A, Bach C, et al. J Neurochem 1994; 63: 456-464.
8. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. J Biol Chem 1994; 268: 23422-23426.
9. Leung E, Walsh LKM, Pulido-Rios MT, Eglen RM. Br J Pharmacol 1996; 117: 926-930.
10. Cushing DJ, Zgombick JM, Nelson DL, Cohen ML. J Pharmacol Exp Ther 1996; 277: 1560-1566.
11. Martin GR, Wilson RJ. Br J Pharmacol 1995; 114: 383.
12. Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A. Mol Pharmol 1995; 47: 99-103.
13. Ruat M, Trafiffort E, Leurs R, et al. Proc Natl Acad Sci USA 1993; 90: 8547-8551.
14. Roth BL, Craigo SC, Choudhary MS, et al. J Pharmacol 1996; 117: 926-930.
15. Meltzer HY. Neuropsychopharmacology 1999; 21 (Suppl 2): 106S-115S.
16. To ZP, Bonhaus DW, Eglen RM, Jakeman LB. Br J Pharmacol 1995; 115: 107-116.
17. Gustafan EL, Durkin MM, Bard JA, Zgombick J, Branchek TA. Br J Pharmacol 1996; 117: 657-666.
18. Forbes IT, Dabbs S, Duckworth DM, et al. J Med Chem 1998; 41: 655-657.
19. Kikuchi C, Nagaso H, Hirayama T, Koyama M. J Med Chem 1999; 42: 533-535.
20. Kikuchi C, Ando Y, Watanabe Y, Nagaso H, Okuno M, Koyama M. J Med Chem 2002; 45: 2197-2206.
21. Kikuchi C, Nagaso H, Hirayama T, Koyama M. Bioorganic & Med Chem Lett, submitted.
22. Suzuki K, Inoue O, Hashimoto K, Yamasaki T, Kuchiki M, Tamate K. Appl Radiat Isot 1985; 36: 971-976.
23. Takei M, Kida T, Suzuki K. Appl Radiat Isot 2001; 55: 229-234.